Nasal Microbiome, COVID-19 Clinical Trial
The Importance of the Nasal Microbiome in Transmission and Disease
The aim of this exploratory, hypothesis-generating study is to investigate the composition of the nasal microbiome in order to compare 1: COVID-positive and negative individuals, 2. Patients with smell loss and controls without smell loss; and 3. patients using intranasal glucocorticoids and non-users.
Hypotheses: The nasal microbiome in COVID-positive patients does not differ from healthy COVID-negative patients. The nasal microbiome in patients suffering from post COVID-19 olfactory dysfunction does not differ from healthy controls with normal olfaction. The nasal microbiome in non-COVID-patients with anosmia does not differ from non-COVID controls with normal sense of smell. Intra-nasal glucocorticoids do not affect the nasal microbiome. Methods: For all patients we will obtain a relevant medical history; an ear-, nose-, and throat examination; Sino-Nasal Outcome Test-22, score; Sniffin' Sticks TDI score; and taste screening results. The microbiome will be evaluated using swabs from the nasal cavity and analysed using next-generation sequencing targeting 16S and 18S ribosomal RNA at the Department of Bacteria, Parasite & Fungi at Staten Serum Institute, Copenhagen, Denmark. ;